(Adds background)
Dec 9 (Reuters) - The European Union's health regulator
on Friday raised concerns over the decreasing effectiveness of
COVID-19 antibody therapies to treat patients as emerging virus
variants are challenging treatment approaches.
The World Health Organization (WHO) and the U.S. Food and
Drug Administration have both gone a step further and pulled
recommendations for some monoclonal antibodies on the basis that
Omicron and the variant's latest offshoots have likely rendered
these options obsolete.
Monoclonal antibodies are designed to neutralise the
SARS-CoV-2 virus by binding to the spike protein on its surface,
but the virus has been evolving, causing changes in this
protein, affecting how the antibodies bind to them.
"Although it is not yet known to what extent the reduced
neutralising activity translates into reduced benefits for
patients, healthcare professionals will need to consider
alternative treatments, especially if subvariants such as BQ.1
and BQ.1.1 become prevalent," the European Medicines Agency
(EMA) said.
New offshoots of the dominant BA.5 subvariant of Omicron
known as BQ.1 and BQ.1.1 are among the more than 300 sublineages
of the Omicron variant circulating globally, 95% of which are
direct descendants of BA.5, according to the WHO.
The Emergency Task Force of the EMA said antiviral
alternatives such as Pfizer's PFE.N Paxlovid and Gilead's
GILD.O remdesivir can be considered, saying that they are
expected to retain their activity against the emerging strains.
AstraZeneca's AZN.L Evusheld, Celltrion's 091990.KQ
Regkirona, Roche's ROG.S Ronapreve and GSK-Vir's GSK.L
VIR.O Xevudy are monoclonal antibodies approved in the EU for
COVID-19.
The EMA added that it would consider any required updates to
labels of the individual therapies.
<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Factbox: What are the new BQ.1 and BQ.1.1 coronavirus variants,
and why it matters https://reut.rs/3VUBnoS
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>
(Reporting by Pushkala Aripaka and Yadarisa Shabong in
Bengaluru; Editing by Krishna Chandra Eluri and Shounak
Dasgupta)
((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; Mobile:
+91 852 751 3793))